Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 858

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 858
---
5. There were no outstanding securities considered anti-dilutive for computation of diluted net loss per share for the three months ended March 31, 2024.

|                                                                         |     | Three Months Ended 
 March 31,          |        2025 |   |     |   |        2024 |   |
|:------------------------------------------------------------------------|:----|:-------------------|------------:|:--|:----|:--|------------:|:--|
| Net loss (in thousands)                                                 |     | $                  |        (665 | ) |     | $ |      (1,506 | ) |
| Net loss per share — basic and diluted                                  |     | $                  |       (0.01 | ) |     | $ |       (0.01 | ) |
| Weighted average number of shares during the period — basic and diluted |     |                    | 160,000,000 |   |     |   | 160,000,000 |   |

**Note 9. Subsequent Events Scilex Bio JV On April 17, 2025, Scilex and IPMC Company formed a joint venture, Scilex Bio, Inc. (“Scilex Bio”), to develop and commercialize a next-generation reversible MAO-B Inhibitor, a novel inhibitor of aberrant GABA production in reactive astrocytes for the treatment of obesity and neurodegenerative diseases including Alzheimer’s disease. Scilex contributed 5.0 million shares of Semnur Common Stock owned by Scilex to Scilex Bio in exchange for a 60% ownership interest in Scilex Bio and IPMC Company contributed certain assets to Scilex Bio in exchange for a 40% ownership interest in Scilex Bio. F-97

Amendment No. 2 to Merger Agreement

The Merger Agreement was amended on July 22, 2025, pursuant to Amendment No. 2 to Agreement and Plan of Merger (“Amendment No. 2 to Merger Agreement”), by and among Denali, Merger Sub and the Company. Among other things, Amendment No. 2 to Merger Agreement modifies the definitions of the Exchange Ratio (as defined in Amendment No. 2 to Merger Agreement) and Merger Consideration (as defined in Amendment No. 2 to Merger Agreement) to facilitate the issuance of additional shares of the Company’s common stock prior to the closing of the Business Combination in connection with any